Arene-ruthenium(II) acylpyrazolonato complexes: Apoptosis-promoting effects on human cancer cells

Journal of Medicinal Chemistry

Volumn 57, Issue 11, 2014, Pages 4532-4542

  Pettinari, Riccardo ^a   Pettinari, Claudio ^a   Marchetti, Fabio ^a   Skelton, Brian W ^b   White, Allan H ^b   Bonfili, Laura ^a   Cuccioloni, Massimiliano ^a   Mozzicafreddo, Matteo ^a   Cecarini, Valentina ^a   Angeletti, Mauro ^a   Nabissi, Massimo ^a   Eleuteri, Anna Maria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE DERIVATIVE; BIPHENYL DERIVATIVE; CASPASE; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; PYRAZOLE DERIVATIVE; RUTHENIUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BIOSENSOR; CANCER CELL LINE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IC 50; INFRARED SPECTROSCOPY; LIGAND BINDING; MTT ASSAY; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL CYCLE; CELL LINE, TUMOR; COORDINATION COMPLEXES; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PYRAZOLONES; RUTHENIUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84902436633     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500458c     Document Type: Article

References (48)

1. Wang, D.; Lippard, S. J. Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discovery 2005, 4, 307-320 (Pubitemid 41130944)
2. Wheate, N. J.; Walker, S.; Craig, G. E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Trans. 2010, 39, 8113-8127
3. Heffeter, P.; Jungwirth, U.; Jakupec, M.; Hartinger, C.; Galanski, M.; Elbling, L.; Micksche, M.; Keppler, B. K.; Berger, W. Resistance against novel anticancer metal compounds: Differences and similarities Drug Resist. Updates 2008, 11, 1-16
4. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. Antitumor metal compounds: More than theme and variations Dalton Trans. 2008, 183-194 (Pubitemid 350278321)
5. Barry, N. P. E.; Sadler, P. J. Exploration of the medical periodic table: Towards new targets Chem. Commun. 2013, 49, 5106-5131
6. Levina, A.; Mitra, A.; Lay, P. A. Recent developments in ruthenium anticancer drugs Metallomics 2009, 1, 458-470
7. Suss-Fink, G. Arene ruthenium complexes as anticancer agents Dalton Trans. 2010, 39, 1673-1688
8. Ang, W. H.; Casini, A.; Sava, G.; Dyson, P. J. Organometallic ruthenium-based antitumor compounds with novel modes of action J. Organomet. Chem. 2011, 696, 989-998
9. Bergamo, A.; Gaiddon, C.; Schellens, J. H.; Beijnen, J. H.; Sava, G. Approaching tumour therapy beyond platinum drugs: Status of the art and perspectives of ruthenium drug candidates J. Inorg. Biochem. 2012, 106, 90-99
10. Ali, I.; Saleem, K.; Wesselinova, D.; Haque, A. DNA binding, hemolytic and anticancer assays of curcumin I based ligands and their ruthenium (III) complexes Med. Chem. Res. 2013, 22, 1386-1398
11. Ali, I.; Wani, W. A.; Saleem, K.; Wesselinova, D. Syntheses, DNA binding and anticancer profiles of L-Glutamic acid ligand and its copper(II) and ruthenium(III) complexes Med. Chem. 2013, 9, 11-21
12. Sava, G.; Zorzet, S.; Turrin, C.; Vita, F.; Soranzo, M.; Zabucchi, G.; Cocchietto, M.; Bergamo, A.; Di Giovine, S.; Pezzoni, G.; Sartor, L.; Garbisa, S. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen Clin. Cancer Res. 2003, 9, 1898-1905 (Pubitemid 36554618)
13. Pacor, S.; Zorzet, S.; Cocchietto, M.; Bacac, M.; Vadori, M.; Turrin, C.; Gava, B.; Castellarin, A.; Sava, G. Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment J. Pharmacol. Exp. Ther. 2004, 310, 737-744 (Pubitemid 38988920)
14. Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. From bench to bedside-preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H- indazole)ruthenate(III)] (KP1019 or FFC14A) J. Inorg. Biochem. 2006, 100, 891-904 (Pubitemid 44308176)
15. Hartinger, C. G.; Jakupec, M. A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P. J.; Keppler, B. K. KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients Chem. Biodivers. 2008, 5, 2140-2155
16. Ang, W. H.; Dyson, P. J. Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy Eur. J. Inorg. Chem. 2006, 4003-4018
17. Dyson, P. J. Systematic design of a targeted organometallic antitumor drug in pre-clinical development Chimia 2007, 61, 698-703
18. Ang, W. H. Development of organometallic ruthenium(II) anticancer (RAPTA) drugs Chimia 2007, 61, 140-142
19. Peacock, A. F. A.; Sadler, P. J. Medicinal organometallic chemistry: Designing metal arene complexes as anticancer agents Chem.-Asian J. 2008, 3, 1890-1899
20. Dougan, S. J.; Sadler, P. J. The design of organometallic ruthenium arene anticancer agents Chimia 2007, 61, 704-715
21. Yan, K.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes Chem. Commun. 2005, 4764-4776 (Pubitemid 41509143)
22. Melchart, M.; Sadler, P. J. Ruthenium arene anticancer complexes. In Bioorganometallics: Biomolecules, Labeling, Medicine; Jaouen, G., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2006; pp 39-64.
23. Morris, R. E.; Aird, R. E.; Murdoch, P.; del, S.; Chen, H.; Cummings, J.; Hughes, N. D.; Parsons, S.; Parkin, A.; Boyd, G.; Jodrell, D. I.; Sadler, P. J. Inhibition of cancer cell growth by ruthenium(II) arene complexes J. Med. Chem. 2001, 44, 3616-3621 (Pubitemid 33026669)
24. Aird, R. E.; Cummings, J.; Ritchie, A. A.; Muir, M.; Morris, R. E.; Chen, H.; Sadler, P. J.; Jodrell, D. I. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer Br. J. Cancer 2002, 86, 1652-1657 (Pubitemid 34628122)
25. Fernandez, R.; Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler, P. J. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes Chem.-Eur. J. 2004, 10, 5173-5179
26. Habtemariam, A.; Melchart, M.; Fernandez, R.; Parsons, S.; Oswald, I. D.; Parkin, A.; Fabbiani, F. P.; Davidson, J. E.; Dawson, A.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands J. Med. Chem. 2006, 49, 6858-6868 (Pubitemid 44749753)
27. Scolaro, C.; Bergamo, A.; Brescacin, L.; Delfino, R.; Cocchietto, M.; Laurenczy, G.; Geldbach, T. J.; Sava, G.; Dyson, P. J. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes J. Med. Chem. 2005, 48, 4161-4171 (Pubitemid 40803517)
28. Marchetti, F.; Pettinari, C.; Pettinari, R.; Cerquetella, A.; Cingolani, A.; Chan, E. J.; Kozawa, K.; Skelton, B. W.; White, A. H.; Wanke, R.; Kuznetsov, M. L.; Martins, L. M. D. R. S.; Pombeiro, A. J. L. Arene ruthenium(II) 4-Acyl-5-pyrazolonate derivatives: coordination chemistry, redox properties, and reactivity Inorg. Chem. 2007, 46, 8245-8257
29. Marchetti, F.; Pettinari, C.; Pettinari, R. Acylpyrazolone ligands: Synthesis, structures, metal coordination chemistry and applications Coord. Chem. Rev. 2005, 249, 2909-2945 (Pubitemid 41643176)
30. Pettinari, C.; Pettinari, R.; Fianchini, M.; Marchetti, F.; Skelton, B. W.; White, A. H. Syntheses, structures, and reactivity of new pentamethylcyclopentadienyl-rhodium(III) and -iridium(III) 4-acyl-5-pyrazolonate complexes Inorg. Chem. 2005, 44, 7933-7942 (Pubitemid 41619095)
31. Geary, W. J. The use of conductivity measurements in organic solvents for the characterization of coordination compounds Coord. Chem. Rev. 1971, 7, 81-122
32. Kruck, T. Trifluorophosphinecomplexes of transition metals Angew. Chem., Int. Ed. Engl. 1967, 6, 53-67
33. Collong, W.; Kruck, T. Metal trifluorophosphine complexes. Hexakis(trifluorophosphine)vanadium(0) synthesis, chemical properties, and reactions Chem. Ber. 1990, 123, 1655-1656
34. Tardito, S.; Isella, C.; Medico, E.; Marchiò, L.; Bevilacqua, E.; Hatzoglou, M.; Bussolati, O.; Franchi-Gazzola, R. The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells J. Biol. Chem. 2009, 284, 24306-24319
35. Volarevic, V.; Vujic, J. M.; Milovanovic, M.; Kanjevac, T.; Volarevic, A.; Trifunovic, S. R.; Arsenijevic, N. Cytotoxic effects of palladium (II) and platinum (II) complexes with O,O′-dialkyl esters of (S,S)-ethylenediamine- N,N′-di-2-(4-methyl) pentanoic acid on human colon cancer cell lines J. BUON 2013, 18, 131-137
36. Boulares, A. H.; Yakovlev, A. G.; Ivanova, V.; Stoica, B. A.; Wang, G.; Iyer, S.; Smulson, M. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells J. Biol. Chem. 1999, 274, 22932-22940
37. Levine, A. J.; Momand, J.; Finlay, C. A. The p53 tumour suppressor gene Nature 1991, 351, 453-456 (Pubitemid 21896613)
38. Reed, J. C. Bcl-2 and the regulation of programmed cell death J. Cell. Biol. 1994, 124, 1-6 (Pubitemid 24054605)
39. Bevington, P. R.; Robinson, D. K. Data Reduction and Error Analysis for the Physical Sciences; McGraw-Hill: New York, 1992.
40. Sheldrick, G. M. A short history of SHELX Acta Crystallogr., Sect. A: Found. Crystallogr. 2008, 64, 112-122
41. Mosmann, T. J. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays Immunol. Methods 1983, 65, 55-63
42. Bradford, M. M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding Anal. Biochem. 1976, 72, 248-254
43. Buonanno, F.; Quassinti, L.; Bramucci, M.; Amantini, C.; Lucciarini, R.; Santoni, G.; Iio, H.; Ortenzi, C. Chem.-Biol. Interact. 2008, 176, 151-164
44. Amici, M.; Bonfili, L.; Spina, M.; Cecarini, V.; Calzuola, I.; Marsili, V.; Angeletti, M.; Fioretti, E.; Tacconi, R.; Gianfranceschi, G. L.; Eleuteri, A. M. Wheat sprout extract induces changes on 20S proteasomes functionality Biochimie 2008, 90, 790-801
45. Davies, R. J.; Edwards, P. R.; Watts, H. J.; Lowe, C. R.; Buckle, P. E.; Yeung, D.; Kinning, T. M.; Pollard-Knight, D. V. The resonant mirror: A versatile tool for the study of biomolecular interaction. In Techniques in Protein Chemistry V; Crabb, J. W., Ed.; Academic Press: San Diego, 1994; pp 285-292.
46. Eriksson, S.; Kim, S. K.; Kubista, M.; Nordén, B. Binding of 4′,6-diamidino-2-phenylindole (DAPI) to AT regions of DNA: Evidence for an allosteric conformational change Biochemistry 1993, 32, 2987-2998 (Pubitemid 23110140)
47. Burres, N. S.; Frigo, A.; Rasmussen, R. R.; Mc Alpine, J. B. A colorimetric microassay for the detection of agents that interact with DNA J. Nat. Prod. 1992, 55, 1582-1587
48. Le Pecq, J. B.; Paoletti, C. A fluorescent complex between ethidium bromide and nucleic acids. Physical-chemical characterization J. Mol. Biol. 1967, 27, 87-106